Senseonics (NYSEAMERICAN:SENS) released its earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01, Briefing.com reports. Senseonics had a negative return on equity of 406.72% and a negative net margin of 828.76%. The firm had revenue of $2.90 million for the quarter, compared to the consensus estimate of $2.95 million. The firm’s revenue was up 866.7% on a year-over-year basis.
Senseonics (NYSEAMERICAN:SENS) opened at $3.07 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.93 and a quick ratio of 2.81. Senseonics has a 12-month low of $1.26 and a 12-month high of $3.67. The stock has a market capitalization of $413.30 and a price-to-earnings ratio of -6.14.
Separately, Canaccord Genuity reissued a “buy” rating on shares of Senseonics in a research report on Friday, March 2nd.
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.